Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Convertible Debt: 2022-2025

Historic Convertible Debt for ImmunityBio (IBRX) over the last 3 years, with Sep 2025 value amounting to $500.8 million.

  • ImmunityBio's Convertible Debt fell 14.83% to $500.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $500.8 million, marking a year-over-year decrease of 14.83%. This contributed to the annual value of $461.9 million for FY2024, which is 19.95% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Convertible Debt is $500.8 million, which was up 1.77% from $492.1 million recorded in Q2 2025.
  • ImmunityBio's 5-year Convertible Debt high stood at $588.0 million for Q3 2024, and its period low was $165.3 million during Q3 2023.
  • Over the past 3 years, ImmunityBio's median Convertible Debt value was $496.4 million (recorded in 2025), while the average stood at $468.5 million.
  • Examining YoY changes over the last 5 years, ImmunityBio's Convertible Debt showed a top increase of 255.73% in 2024 and a maximum decrease of 19.95% in 2024.
  • Quarterly analysis of 4 years shows ImmunityBio's Convertible Debt stood at $241.3 million in 2022, then skyrocketed by 139.13% to $577.0 million in 2023, then decreased by 19.95% to $461.9 million in 2024, then declined by 14.83% to $500.8 million in 2025.
  • Its last three reported values are $500.8 million in Q3 2025, $492.1 million for Q2 2025, and $485.7 million during Q1 2025.